Disease group | Number of associated approved drugs | Number of drugs with post-approval indication | Percent with post-approval indication (%) |
---|---|---|---|
Neoplasms | 22 | 12 | 54 |
Skin and connective tissue disease | 19 | 9 | 48 |
Digestive system diseases | 12 | 5 | 41 |
Musculoskeletal diseases | 10 | 4 | 40 |
Endocrine system diseases | 8 | 3 | 38 |
Respiratory tract diseases | 9 | 3 | 33 |
Nutritional and metabolic diseases | 18 | 6 | 33 |
Pathological conditions, signs and symptoms | 7 | 2 | 29 |
Hemic and lymphatic disease | 11 | 3 | 27 |
Nervous system disease | 52 | 14 | 26 |
Infections | 27 | 7 | 25 |
Cardiovascular disease | 28 | 7 | 25 |
Immune system diseases | 13 | 3 | 23 |
Female urogenital diseases and pregnancy complications | 14 | 3 | 21 |
Chemically induced disorders | 5 | 2 | 20 |
Male urogenital diseases | 17 | 3 | 18 |
Stomatognathic diseases | 1 | 0 | 0 |
Eye diseases | 5 | 0 | 0 |
Congenital, hereditary diseases, and neonatal and abnormalities | 8 | 0 | 0 |
Wounds and injuries | 2 | 0 | 0 |